PHARMANUTRA SPA (PHN.MI) Stock Price, Forecast & Analysis
Europe - BIT:PHN - IT0005274094 - Common Stock
PHN.MI Key Statistics, Chart & Performance
The current stock price of PHN.MI is 51.65 EUR. In the past month the price increased by 6.39%. In the past year, price decreased by -7.36%.
PHN.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| OR.PA | L'OREAL | 28.49 | 193.86B | ||
| LOR.DE | L'OREAL | 28.29 | 192.50B | ||
| BEI.DE | BEIERSDORF AG | 23.27 | 22.30B | ||
| ITP.PA | INTERPARFUMS SA | 15.51 | 2.27B | ||
| ICOS.MI | INTERCOS SPA | 23.35 | 1.10B | ||
| ONTEX.BR | ONTEX GROUP NV | 51.75 | 511.39M | ||
| ENV.MI | ENERVIT | 15.04 | 66.93M | ||
| JBOG.PA | JACQUES BOGART | N/A | 68.09M |
Related stock screener links
About PHN.MI
Company Profile
Pharmanutra SpA develops nutraceutical products and medical devices. The company is headquartered in Pisa, Pisa and currently employs 134 full-time employees. The company went IPO on 2017-07-18. The firm develops nutraceutical products and medical devices. The company focuses on studying and producing formulations that are backed up in scientific research. The company is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The firm offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.
Company Info
PHARMANUTRA SPA
Via delle Lenze n. 216/B
Pisa PISA IT
Employees: 118
Phone: 390507846500
PHARMANUTRA SPA / PHN.MI FAQ
What does PHN do?
Pharmanutra SpA develops nutraceutical products and medical devices. The company is headquartered in Pisa, Pisa and currently employs 134 full-time employees. The company went IPO on 2017-07-18. The firm develops nutraceutical products and medical devices. The company focuses on studying and producing formulations that are backed up in scientific research. The company is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The firm offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.
What is the current price of PHN stock?
The current stock price of PHN.MI is 51.65 EUR. The price increased by 0.1% in the last trading session.
Does PHARMANUTRA SPA pay dividends?
PHARMANUTRA SPA (PHN.MI) has a dividend yield of 2.28%. The yearly dividend amount is currently 0.85.
What is the ChartMill technical and fundamental rating of PHN stock?
PHN.MI has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the expected growth for PHN stock?
The Revenue of PHARMANUTRA SPA (PHN.MI) is expected to grow by 14.06% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for PHN stock?
PHARMANUTRA SPA (PHN.MI) currently has 118 employees.
What is PHARMANUTRA SPA worth?
PHARMANUTRA SPA (PHN.MI) has a market capitalization of 499.97M EUR. This makes PHN.MI a Small Cap stock.
PHN.MI Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to PHN.MI. When comparing the yearly performance of all stocks, PHN.MI is a bad performer in the overall market: 66.14% of all stocks are doing better.
PHN.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to PHN.MI. PHN.MI gets an excellent profitability rating and is at the same time showing great financial health properties.
PHN.MI Financial Highlights
Over the last trailing twelve months PHN.MI reported a non-GAAP Earnings per Share(EPS) of 2.45. The EPS increased by 20.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 13.48% | ||
| ROA | 20.41% | ||
| ROE | 38.54% | ||
| Debt/Equity | 0.28 |
PHN.MI Forecast & Estimates
7 analysts have analysed PHN.MI and the average price target is 82.62 EUR. This implies a price increase of 59.96% is expected in the next year compared to the current price of 51.65.
For the next year, analysts expect an EPS growth of 5.49% and a revenue growth 14.06% for PHN.MI